Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.  The oral presentation will be given by Paulo Hoff, M.D., Professor of Medicine and Chairman of Medical Oncology at the University of Sao Paulo, Brazil and former lead investigator for the capecitabine (Xeloda(R)) Phase 3 approval study in metastatic colorectal cancer.  

Of the 38 patients enrolled in the Phase II study, 27 patients were previously refractory to a 5-FU based regimen.  A Phase 3 randomized double-blind trial comparing perifosine + capecitabine vs. placebo + capecitabine in 5-FU refractory patients with advanced refractory colorectal cancer (X-PECT trial), under Special Protocol Assessment (SPA) from the FDA, is currently open and enrolling patients at multiple centers throughout the U.S.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

SOURCE Keryx Biopharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
MAPK4 may play a key role in triple-negative breast cancer